Trials / Not Yet Recruiting
Not Yet RecruitingNCT07239986
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
An Open-label, Multicenter Phase 2 Clinical Study on the Efficacy and Safety of BB102 in Patients With Advanced or Unresectable FGF19-overexpressing Hepatocellular Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Broadenbio Ltd., Co. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BB102 | Oral BB102 Tablets in two dosage |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
- First posted
- 2025-11-20
- Last updated
- 2025-11-20
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07239986. Inclusion in this directory is not an endorsement.